Protocol Ledger

NCT06622941 · Phase II · RECRUITING

Study to ONO-4538 in Patients With Rhabdoid Tumor

Interventional Phase II clinical trial protocol NCT06622941 sponsored by Ono Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-25 Enrollment: 23 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06622941
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)23 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06622941
Protocol FieldVerified Registry Value
NCT IdentifierNCT06622941
Consolidated Lead SponsorOno Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment23 participants (ESTIMATED)
Registered Start Date2024-11-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06622941
Hospital Research SiteLocationSite Profile
Nagoya University HospitalNagoya, JapanOpen Hospital Dossier ->
Hokkaido University HospitalSapporo, JapanOpen Hospital Dossier ->
National Cancer Center HospitalChuo-ku, JapanOpen Hospital Dossier ->
Chiba University HospitalChiba, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI